chr4-122827109-C-T
Position:
Variant summary
Our verdict is Likely benign. Variant got -6 ACMG points: 0P and 6B. BP4_ModerateBS2
The NM_001361665.2(FGF2):c.-66C>T variant causes a 5 prime UTR premature start codon gain change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000191 in 1,253,564 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★).
Frequency
Genomes: 𝑓 0.000013 ( 0 hom., cov: 31)
Exomes 𝑓: 0.000020 ( 0 hom. )
Consequence
FGF2
NM_001361665.2 5_prime_UTR_premature_start_codon_gain
NM_001361665.2 5_prime_UTR_premature_start_codon_gain
Scores
3
3
12
Clinical Significance
Conservation
PhyloP100: -0.240
Genes affected
FGF2 (HGNC:3676): (fibroblast growth factor 2) The protein encoded by this gene is a member of the fibroblast growth factor (FGF) family. FGF family members bind heparin and possess broad mitogenic and angiogenic activities. This protein has been implicated in diverse biological processes, such as limb and nervous system development, wound healing, and tumor growth. The mRNA for this gene contains multiple polyadenylation sites, and is alternatively translated from non-AUG (CUG) and AUG initiation codons, resulting in five different isoforms with distinct properties. The CUG-initiated isoforms are localized in the nucleus and are responsible for the intracrine effect, whereas, the AUG-initiated form is mostly cytosolic and is responsible for the paracrine and autocrine effects of this FGF. [provided by RefSeq, Jul 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Likely_benign. Variant got -6 ACMG points.
BP4
Computational evidence support a benign effect (MetaRNN=0.17608055).
BS2
High AC in GnomAdExome4 at 22 AD gene.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
FGF2 | NM_001361665.2 | c.-66C>T | 5_prime_UTR_premature_start_codon_gain_variant | 1/3 | ENST00000644866.2 | NP_001348594.1 | ||
FGF2 | NM_001361665.2 | c.-66C>T | 5_prime_UTR_variant | 1/3 | ENST00000644866.2 | NP_001348594.1 | ||
FGF2 | NM_002006.6 | c.334C>T | p.Arg112Trp | missense_variant | 1/3 | NP_001997.5 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
FGF2 | ENST00000644866.2 | c.-66C>T | 5_prime_UTR_premature_start_codon_gain_variant | 1/3 | NM_001361665.2 | ENSP00000494222.1 | ||||
FGF2 | ENST00000644866.2 | c.-66C>T | 5_prime_UTR_variant | 1/3 | NM_001361665.2 | ENSP00000494222.1 |
Frequencies
GnomAD3 genomes AF: 0.0000135 AC: 2AN: 148260Hom.: 0 Cov.: 31
GnomAD3 genomes
AF:
AC:
2
AN:
148260
Hom.:
Cov.:
31
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD4 exome AF: 0.0000199 AC: 22AN: 1105194Hom.: 0 Cov.: 31 AF XY: 0.0000171 AC XY: 9AN XY: 527344
GnomAD4 exome
AF:
AC:
22
AN:
1105194
Hom.:
Cov.:
31
AF XY:
AC XY:
9
AN XY:
527344
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000135 AC: 2AN: 148370Hom.: 0 Cov.: 31 AF XY: 0.00 AC XY: 0AN XY: 72398
GnomAD4 genome
AF:
AC:
2
AN:
148370
Hom.:
Cov.:
31
AF XY:
AC XY:
0
AN XY:
72398
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
ClinVar
Significance: Uncertain significance
Submissions summary: Uncertain:1
Revision: criteria provided, single submitter
LINK: link
Submissions by phenotype
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Feb 28, 2023 | The c.334C>T (p.R112W) alteration is located in exon 1 (coding exon 1) of the FGF2 gene. This alteration results from a C to T substitution at nucleotide position 334, causing the arginine (R) at amino acid position 112 to be replaced by a tryptophan (W). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
BayesDel_addAF
Uncertain
T
BayesDel_noAF
Benign
CADD
Benign
DANN
Uncertain
DEOGEN2
Benign
.;T
Eigen
Benign
Eigen_PC
Benign
FATHMM_MKL
Benign
N
LIST_S2
Benign
T;T
M_CAP
Uncertain
D
MetaRNN
Benign
T;T
MetaSVM
Benign
T
MutationAssessor
Benign
.;N
PrimateAI
Pathogenic
D
PROVEAN
Benign
N;.
REVEL
Benign
Sift
Pathogenic
D;.
Sift4G
Pathogenic
D;D
Polyphen
0.94
.;P
MutPred
Loss of methylation at R112 (P = 7e-04);Loss of methylation at R112 (P = 7e-04);
MVP
ClinPred
D
GERP RS
RBP_binding_hub_radar
RBP_regulation_power_radar
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at